53 completed, 5 unknown, 2 not yet recruiting, 1 recruiting. 23 Phase 4, 12 Phase 3, 11 Phase 2, 10 Not applicable, 6 Phase 1.
Follow Coartem: new trials by email Literature Review of Coartem trials Research Report on Coartem
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium Vivax Tafenoquine (TQ), Chloroquine (CQ), Dihydroartemisinin-piperaquine (DHA-PPQ) - Uncomplicated P. Vivax Mono-infection | Not applicable | Not yet recruiting | Walter Reed Army Institute of Research (WRAIR) | 300 | 2026-05-01 | 2026-04-16 |
| Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria Single dose tafenoquine (10 mg/kg), Dihydroartemisinin-piperaquine (DHA-PPQ), Artemether + Lumefantrine - Uncomplicated Malaria | Phase 4 | Not yet recruiting | Curtin University | 60 | 2026-04-01 | 2026-02-12 |
| Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2) KAE609, SoC (Coartem), KLU156 - Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | Recruiting | Novartis Pharmaceuticals | 120 | 2026-02-12 | 2026-10-15 |
| The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination Therapy Artemether-lumefantrine, Dihydroartemisinin-Piperaquine - Falciparum; Malaria | Phase 4 | Completed | Infectious Diseases Research Collaboration, Uganda | 160 | 2024-05-28 | 2026-07-06 |
| Artemisinin Partial Resistance in Ethiopian Plasmodium Falciparum: A Multisite Clinical, Molecular and In Vitro Study Artemether-Lumefantrine Tab 20-120mg - Malaria (Plasmodium Falciparum), Drug Resistance | Not applicable | Completed | Didier Menard | 277 | 2024-05-01 | 2026-04-14 |
| Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria KLU156, Coartem - Uncomplicated Plasmodium Falciparum Malaria | Phase 3 | Completed | Novartis Pharmaceuticals | 1720 | 2024-03-07 | 2026-01-27 |
| Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2) KAE609, SoC (Coartem), KLU156 - Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | Completed | Novartis Pharmaceuticals | 60 | 2024-01-23 | 2026-05-07 |
| Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali Artesunate-amodiaquine combination, Primaquine Phosphate, Artemether-lumefantrine - Malaria,Falciparum | Phase 2 | Completed | London School of Hygiene and Tropical Medicine | 100 | 2022-10-17 | 2024-10-01 |
| Controlled Human Malaria Infection Transmission Model - Phase A PfSPZ Challenge, Sulfadoxine-Pyrimethamine, Piperaquine - Malaria,Falciparum | Phase 1 / Phase 2 | Suspended | University of Oxford | 44 | 2022-08-22 | 2024-05-23 |
| Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia Amodiaquine-artesunate (ASAQ), Artemether+Lumefantrine (AL) - Plasmodium Falciparum, Malaria | Phase 4 | Completed | Centers for Disease Control and Prevention | 352 | 2022-08-09 | 2024-05-07 |
| To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria Cipargamin, IV Artesunate, Coartem - Severe Malaria | Phase 2 | Completed | Novartis Pharmaceuticals | 254 | 2022-03-07 | 2026-04-09 |
| Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Malaria in Cameroon Artesunate-amodiaquine drug combination, Artemether-lumefantrine drug combination - Falciparum Malaria | Phase 4 | Unknown | University of Yaounde 1 | 184 | 2021-04-05 | 2021-04-02 |
| Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria KAF156, LUM-SDF, Coartem - Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | Completed | Novartis Pharmaceuticals | 295 | 2021-02-16 | 2026-05-07 |
| Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso Artemether-lumefantrine (AL), Pyronaridine-artesunate (PA) - Covid-19, Malaria | Phase 3 | Completed | Liverpool School of Tropical Medicine | 143 | 2021-01-08 | 2024-02-23 |
| Malaria High-Risk Populations in Namibia Presumptive treatment with Artemether-lumefantrine (AL), Enhanced vector control - Malaria | Phase 4 | Completed | University of California, San Francisco | 3302 | 2019-10-31 | 2020-11-03 |
| Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa... Chloroquine Phosphate, PfSPZ Challenge, Pyrimethamine - Malaria | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 252 | 2019-05-23 | 2022-07-12 |
| Dried Leaf Artemisia (DLA) Compared to Artemisinin Combination Therapy (ACT) vs Malaria ACT, DLA1, DLA2 - Malaria | Phase 2 | Withdrawn | Worcester Polytechnic Institute | 2018-08-20 | 2021-10-14 | |
| Effect of Artemisinin-based Combination Therapies on Schistosomiasis on Malaria Co-infection Artesunate-Pyronaridine, Artemether-Lumefantrine, Artefenomel-Ferroquine - Schistosomiasis Haematobia | Phase 2 | Completed | Centre de Recherche Médicale de Lambaréné | 54 | 2018-07-31 | 2020-02-11 |
| Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali PfSPZ Vaccine, Normal Saline, artemether 20mg/lumefantrine 120mg (AL) - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 478 | 2018-05-14 | 2021-08-20 |
| Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic Standard RDT and HS-RDT, Artemether-lumefantrine, Primaquine Phosphate - Plasmodium Falciparum Malaria | Phase 4 | Completed | University of California, San Francisco | 39968 | 2017-11-28 | 2021-02-23 |
Showing 20 of 64. Sign in to see all of them.
Malaria (43) · Malaria, Falciparum (26) · Malaria, Vivax (4) · Acquired Immunodeficiency Syndrome (2) · Anemia (2) · HIV Infections (2) · Pneumonia (2) · COVID-19 (1) · Disease (1) · Fasting (1) · Infections (1) · Parasitic Diseases (1) · Recurrence (1) · Schistosomiasis haematobia (1) · Tuberculosis (1)
London School of Hygiene and Tropical Medicine (8) · Novartis Pharmaceuticals (7) · Centers for Disease Control and Prevention (4) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Research Institute for Tropical Medicine, Philippines (3) · Dafra Pharma (2) · Makerere University (2) · Medicines for Malaria Venture (2) · Royal Tropical Institute (2) · University of California, San Francisco (2) · University of Oxford (2) · University of Yaounde 1 (2) · Albert Schweitzer Hospital (1) · Bandim Health Project (1) · Boston University (1)
Kenya (13) · Mali (13) · Burkina Faso (10) · Uganda (10) · Gabon (9) · Ghana (7) · Côte d’Ivoire (6) · Democratic Republic of the Congo (5) · Rwanda (5) · Mozambique (4) · Tanzania (4) · Thailand (3) · The Gambia (3) · Benin (2) · Brazil (2)
Patrick E Duffy, M.D. (4) · Andreas Martensson, PhD (2) · Claude Oeuvray, PhD (2) · Wilfred F Mbacham, ScD (2) · Adam Bennett, MA, PhD (1) · Alassane Dicko (1) · Alexandre Macedo de Oliveira, MD (1) · Alfred Tiono, PhD (1) · Ambrose O Talisuna, PhD (1) · Brian Greenwood, MD (1) · Brian M Greenwood, FRCP, FRS (1) · Brian Vesely, PhD (1) · Brioni R Moore, PhD (1)
PMID 23433102, PMID 26666916, PMID 37327809, PMID 18575626, PMID 19102746, PMID 19366448, PMID 19469703, PMID 19622553, PMID 19769536, PMID 20417857, PMID 20877714, PMID 21947399, PMID 23113947, PMID 25297720, PMID 25436614, PMID 25626448, PMID 26258474, PMID 26283750, PMID 26377070, PMID 26505753, PMID 27599612, PMID 28732068, PMID 28862132, PMID 29210351, PMID 29311086, PMID 29764419, PMID 29866116, PMID 29961848, PMID 30384846, PMID 30860013, PMID 30898164, PMID 32118199, PMID 32133163, PMID 32420402, PMID 32747827, PMID 33289099, PMID 34107963, PMID 34410358, PMID 34551228, PMID 34801112, PMID 34930267, PMID 35726133, PMID 36036611, PMID 36099312, PMID 36289202, PMID 36315579, PMID 36534705, PMID 37611122, PMID 37640962, PMID 37754284